Diabetic ketoacidosis diagnostic study of choice
|
Diabetic ketoacidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diabetic ketoacidosis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Diabetic ketoacidosis diagnostic study of choice |
|
Diabetic ketoacidosis diagnostic study of choice in the news |
|
Risk calculators and risk factors for Diabetic ketoacidosis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2] Hibatullah Abdul Aleem, M.B.B.S[3]
Overview
There is no single confirmatory test for diabetic ketoacidosis (DKA); the diagnosis is biochemical and requires the simultaneous presence of hyperglycemia (or known diabetes), ketonemia or ketonuria, and high-anion gap metabolic acidosis. The most clinically useful single laboratory test is quantitative plasma β-hydroxybutyrate (BOHB), which is now the guideline-preferred ketone measurement over the semiquantitative nitroprusside (urine or serum) test for both diagnosis and monitoring. Diagnostic and severity criteria differ across the American Diabetes Association (ADA), Joint British Diabetes Societies (JBDS), and ISPAD, and these differences are preserved rather than reconciled.
Diagnostic Study of Choice
Gold standard or study of choice
- There is no single diagnostic study of choice for diabetic ketoacidosis; diagnosis requires the complete biochemical triad of hyperglycemia or known diabetes, ketonemia, and high-anion gap metabolic acidosis.[1][2]
- Diagnosis requires either hyperglycemia or a prior history of diabetes, because approximately 10% of DKA is euglycemic and a normal glucose does not exclude the diagnosis, notably with SGLT2 inhibitors.[1]
- DKA and hyperosmolar hyperglycemic state (HHS) frequently co-present, and up to one-third of SGLT2 inhibitor-associated DKA presents with a lower or near-normal glucose.[1][3]
- The diagnostic study of choice for ketosis is quantitative plasma β-hydroxybutyrate (BOHB), the predominant circulating ketone in DKA; JBDS and ISPAD recommend serum BOHB over urine ketones when available because it is more accurate.[2]
Preferred ketone study: plasma β-hydroxybutyrate
- A validated diagnostic cutoff is BOHB ≥3.0 mmol/L, which corresponds to a bicarbonate of 18 mEq/L; in the derivation study a bicarbonate of 18 mEq/L corresponded to BOHB of 3.0 mmol/L in children and 3.8 mmol/L in adults.[2][4]
- Point-of-care capillary BOHB is as sensitive as the urine dipstick for DKA but substantially more specific with a high negative predictive value, reducing unnecessary DKA work-ups in hyperglycemic patients; a point-of-care BOHB >1.5 mmol/L is the validated screening cutoff, distinct from the ≥3.0 mmol/L diagnostic threshold.[5]
Why nitroprusside testing is inferior
- The nitroprusside reaction detects acetoacetate and acetone but not β-hydroxybutyrate, the dominant ketone in DKA.[6]
- Because BOHB predominates early and during evolving acidosis, urine or serum nitroprusside testing can underestimate ketosis at presentation and paradoxically appear to worsen during treatment as BOHB is converted back to acetoacetate.[6]
Ancillary studies to establish diagnosis and severity
- All patients require electrolytes, phosphate, BUN, creatinine, urinalysis, CBC with differential, A1C, and ECG; sodium should be corrected for hyperglycemia to avoid misinterpreting pseudohyponatremia.[2]
- Venous pH is acceptable in place of arterial sampling for diagnosis.[2]
- The anion gap and BOHB, rather than bicarbonate, best track ketoacidosis, since large-volume saline can cause a hyperchloremic non-anion-gap acidosis that lowers bicarbonate independently of ketosis.[6]
Comparison of ketone tests for diagnosis of DKA
| Test | Sensitivity | Specificity | NPV |
|---|---|---|---|
| Point-of-care capillary β-hydroxybutyrate (>1.5 mmol/L) | ~98% | 78.6% | 99.7% |
| Urine dipstick (nitroprusside) | ~98% | 35.1% | — |
β-hydroxybutyrate matches the urine dipstick on sensitivity but is markedly more specific, reducing unnecessary work-ups. NPV, negative predictive value.[5]
Diagnostic Criteria
- The diagnosis of diabetic ketoacidosis requires the complete biochemical triad; per ADA 2026, all criteria must be met, with either hyperglycemia or a prior history of diabetes.[1][2]
- Hyperglycemia: glucose >250 mg/dL (ADA); this is de-emphasized in newer guidance, as JBDS uses >200 mg/dL and no glucose threshold is required in known diabetes.[2]
- Metabolic acidosis: venous pH below the normal range with anion gap >10 mEq/L.[2]
- Per ADA severity grading, the anion gap is >10 mEq/L in mild DKA and >12 mEq/L in moderate-to-severe DKA.[2]
- Ketosis: elevated serum (preferred) or urine ketones; BOHB ≥3.0 mmol/L is a validated threshold.[2][4]
Severity grading (ADA, adults)
| Severity | Arterial or venous pH | Bicarbonate (mEq/L) | Mental status |
|---|---|---|---|
| Mild | 7.25–7.30 | 15–18 | Alert |
| Moderate | 7.00–7.24 | 10 to <15 | Alert or drowsy |
| Severe | <7.00 | <10 | Stupor or coma |
Glucose >250 mg/dL and positive ketones apply across all grades. ADA criteria specify arterial pH; venous pH (which runs approximately 0.02–0.03 units lower with closely agreeing bicarbonate) is an acceptable substitute in hemodynamically stable patients without respiratory failure. Pediatric (ISPAD) severity grading uses venous pH and bicarbonate thresholds that differ from the adult criteria.[2][7][8]
References
- ↑ 1.0 1.1 1.2 1.3 American Diabetes Association Professional Practice Committee for Diabetes (2026). "16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S339–S355. doi:10.2337/dc26-S016.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Veauthier B, Levy-Grau B (2024). "Diabetic Ketoacidosis: Evaluation and Treatment". Am Fam Physician. 110 (5): 476–486.
- ↑ American Diabetes Association Professional Practice Committee for Diabetes (2026). "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S183–S215. doi:10.2337/dc26-S009.
- ↑ 4.0 4.1 Sheikh-Ali M, Karon BS, Basu A (2008). "Can Serum Beta-Hydroxybutyrate Be Used to Diagnose Diabetic Ketoacidosis?". Diabetes Care. 31 (4): 643–647. doi:10.2337/dc07-1683. PMID 18184896.
- ↑ 5.0 5.1 Arora S, Henderson SO, Long T, Menchine M (2011). "Diagnostic Accuracy of Point-of-Care Testing for Diabetic Ketoacidosis at Emergency-Department Triage: β-Hydroxybutyrate Versus the Urine Dipstick". Diabetes Care. 34 (4): 852–854. doi:10.2337/dc10-1844. PMID 21307381.
- ↑ 6.0 6.1 6.2 Kilpatrick ES, Butler AE, Ostlundh L, Atkin SL, Sacks DB (2022). "Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis". Diabetes Care. 45 (2): 267–272. doi:10.2337/dc21-2279. PMID 35015079 Check
|pmid=value (help). - ↑ Brandenburg MA, Dire DJ (1998). "Comparison of Arterial and Venous Blood Gas Values in the Initial Emergency Department Evaluation of Patients With Diabetic Ketoacidosis". Ann Emerg Med. 31 (4): 459–465. doi:10.1016/s0196-0644(98)70254-9. PMID 9581143.
- ↑ Kelly AM (2006). "The Case for Venous Rather Than Arterial Blood Gases in Diabetic Ketoacidosis". Emerg Med Australas. 18 (1): 64–67. doi:10.1111/j.1742-6723.2006.00803.x. PMID 16454777.